{"id":917280,"date":"2025-12-08T09:09:43","date_gmt":"2025-12-08T14:09:43","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/neogenomics-to-present-real-world-study-on-comprehensive-genomic-profiling-in-myeloid-malignancies-at-ash-2025\/"},"modified":"2025-12-08T09:09:43","modified_gmt":"2025-12-08T14:09:43","slug":"neogenomics-to-present-real-world-study-on-comprehensive-genomic-profiling-in-myeloid-malignancies-at-ash-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/neogenomics-to-present-real-world-study-on-comprehensive-genomic-profiling-in-myeloid-malignancies-at-ash-2025\/","title":{"rendered":"NeoGenomics to Present Real-World Study on Comprehensive Genomic Profiling in Myeloid Malignancies at ASH 2025"},"content":{"rendered":"

<\/p>\n

NeoGenomics to Present Real-World Study on Comprehensive Genomic Profiling in Myeloid Malignancies at ASH 2025<\/b><\/p>\n

FORT MYERS, Fla.–(BUSINESS WIRE<\/a>)–
\nNeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, will present new data demonstrating how comprehensive genomic profiling (CGP) can refine diagnosis and guide treatment decisions for patients with myeloid malignancies at the 67th American Society of Hematology (ASH) Annual Meeting<\/a>, which is being held Dec. 6\u20139, 2025, in Orlando, Florida.\n<\/p>\n

\nThe poster, \u201c<\/i>Comprehensive genomic profiling refines diagnosis and reveals actionable fusions in myeloid malignancies: A real-world analysis<\/i><\/a>,\u201d <\/i>evaluated outcomes using the Neo Comprehensive Myeloid panel, a next-generation sequencing (NGS) assay that provides a complete view of genomic changes in myeloid cancers. By assessing mutations and fusions in a single test, this CGP panel detects important genomic variants that may otherwise be missed, and supports diagnosis, prognosis, and therapy selection for diseases such as acute myeloid leukemia (AML), myelodysplastic neoplasms (MDS), and myeloproliferative neoplasms (MPN).\n<\/p>\n

\nResearchers analyzed data from 533 patients with myeloid disorders, integrating NeoGenomics\u2019 molecular results with clinical data from national health information exchanges. The analysis found that in about one-third of patients tested, CGP identified pathogenic changes earlier in their disease, leading to diagnostic reclassification in several cases. It also revealed rare but clinically significant fusions\u2014including PDGFRA, PDGFRB, FGFR1, and JAK2\u2014that helped guide targeted treatment decisions.\n<\/p>\n

\n\u201cThis study underscores our leadership in hematologic malignancy diagnostics and our long-standing commitment to improving cancer care in the community setting,\u201d said Warren Stone, President and Chief Operating Officer at NeoGenomics. \u201cPatients living with complex blood cancers rely on timely and definitive answers, and their physicians deserve access to best-in-class molecular tools, regardless of practice location. Our next-generation myeloid CGP solution combines DNA and RNA sequencing in a single, comprehensive assay, providing actionable insights that smaller or DNA-only panels may miss. By expanding access to advanced diagnostics, we are enabling more personalized treatment decisions and working to improve the path to care for every patient, everywhere.\u201d\n<\/p>\n

\nThe study will be presented in session 908A, Outcomes Research: Myeloid Malignancies: Poster III, on December 8 from 6:00 to 8:00 p.m. ET. Conference attendees can also visit Booth #1971 in the ASH 2025 Exhibit Hall to learn more about NeoGenomics\u2019 hematology testing portfolio and ongoing research.\n<\/p>\n

About NeoGenomics<\/b><\/p>\n

NeoGenomics, Inc<\/a>. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom.\n<\/p>\n

Forward Looking Statements<\/b><\/p>\n

\nThis press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as \u201canticipate,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201ccan,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cforecast,\u201d \u201cgoal,\u201d \u201cproject,\u201d \u201cguidance,\u201d \u201cpotential\u201d and other words of similar meaning, although not all forward-looking statements include these words. These forward-looking statements include statements regarding the potential for the Neo Comprehensive Myeloid CGP panel to refine diagnosis and guide treatment decisions for patients with myeloid malignancies. Each forward-looking statement contained in this press release is subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Applicable risks and uncertainties include, among others, the risks identified under the heading “Risk Factors” contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, and filed with the SEC on February 18, 2025, as well as subsequently filed Quarterly Reports on Form 10-Q and the Company’s other filings with the Securities and Exchange Commission.\n<\/p>\n

\nWe caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov<\/a> and in the \u201cInvestors\u201d section of our website at ir.neogenomics.com, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document (unless another date is indicated), and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20251208548164\/en\/<\/a><\/span><\/p>\n

Investor Contact
\n<\/b>
Kendra Webster
\n
InvestorRelations@neogenomics.com<\/a><\/p>\n

Media Contact
\n<\/b>
Andrea Sampson
\n
asampson@sampsonprgroup.com<\/a><\/p>\n

KEYWORDS:<\/b> Florida United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Science Research Pharmaceutical Oncology Health Medical Devices Genetics Clinical Trials<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

NeoGenomics to Present Real-World Study on Comprehensive Genomic Profiling in Myeloid Malignancies at ASH 2025 FORT MYERS, Fla.–(BUSINESS WIRE)– NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, will present new data demonstrating how comprehensive genomic profiling (CGP) can refine diagnosis and guide treatment decisions for patients with myeloid malignancies at the 67th American Society of Hematology (ASH) Annual Meeting, which is being held Dec. 6\u20139, 2025, in Orlando, Florida. The poster, \u201cComprehensive genomic profiling refines diagnosis and reveals actionable fusions in myeloid malignancies: A real-world analysis,\u201d evaluated outcomes using the Neo Comprehensive Myeloid panel, a next-generation sequencing (NGS) assay that provides a complete view of genomic changes in myeloid cancers. By assessing mutations … <\/p>\n

Continue reading “NeoGenomics to Present Real-World Study on Comprehensive Genomic Profiling in Myeloid Malignancies at ASH 2025”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-917280","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nNeoGenomics to Present Real-World Study on Comprehensive Genomic Profiling in Myeloid Malignancies at ASH 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neogenomics-to-present-real-world-study-on-comprehensive-genomic-profiling-in-myeloid-malignancies-at-ash-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NeoGenomics to Present Real-World Study on Comprehensive Genomic Profiling in Myeloid Malignancies at ASH 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NeoGenomics to Present Real-World Study on Comprehensive Genomic Profiling in Myeloid Malignancies at ASH 2025 FORT MYERS, Fla.–(BUSINESS WIRE)– NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, will present new data demonstrating how comprehensive genomic profiling (CGP) can refine diagnosis and guide treatment decisions for patients with myeloid malignancies at the 67th American Society of Hematology (ASH) Annual Meeting, which is being held Dec. 6\u20139, 2025, in Orlando, Florida. The poster, \u201cComprehensive genomic profiling refines diagnosis and reveals actionable fusions in myeloid malignancies: A real-world analysis,\u201d evaluated outcomes using the Neo Comprehensive Myeloid panel, a next-generation sequencing (NGS) assay that provides a complete view of genomic changes in myeloid cancers. By assessing mutations … Continue reading "NeoGenomics to Present Real-World Study on Comprehensive Genomic Profiling in Myeloid Malignancies at ASH 2025"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/neogenomics-to-present-real-world-study-on-comprehensive-genomic-profiling-in-myeloid-malignancies-at-ash-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-08T14:09:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20251208548164r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neogenomics-to-present-real-world-study-on-comprehensive-genomic-profiling-in-myeloid-malignancies-at-ash-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neogenomics-to-present-real-world-study-on-comprehensive-genomic-profiling-in-myeloid-malignancies-at-ash-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"NeoGenomics to Present Real-World Study on Comprehensive Genomic Profiling in Myeloid Malignancies at ASH 2025\",\"datePublished\":\"2025-12-08T14:09:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neogenomics-to-present-real-world-study-on-comprehensive-genomic-profiling-in-myeloid-malignancies-at-ash-2025\\\/\"},\"wordCount\":808,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neogenomics-to-present-real-world-study-on-comprehensive-genomic-profiling-in-myeloid-malignancies-at-ash-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20251208548164r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neogenomics-to-present-real-world-study-on-comprehensive-genomic-profiling-in-myeloid-malignancies-at-ash-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neogenomics-to-present-real-world-study-on-comprehensive-genomic-profiling-in-myeloid-malignancies-at-ash-2025\\\/\",\"name\":\"NeoGenomics to Present Real-World Study on Comprehensive Genomic Profiling in Myeloid Malignancies at ASH 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neogenomics-to-present-real-world-study-on-comprehensive-genomic-profiling-in-myeloid-malignancies-at-ash-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neogenomics-to-present-real-world-study-on-comprehensive-genomic-profiling-in-myeloid-malignancies-at-ash-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20251208548164r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2025-12-08T14:09:43+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neogenomics-to-present-real-world-study-on-comprehensive-genomic-profiling-in-myeloid-malignancies-at-ash-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neogenomics-to-present-real-world-study-on-comprehensive-genomic-profiling-in-myeloid-malignancies-at-ash-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neogenomics-to-present-real-world-study-on-comprehensive-genomic-profiling-in-myeloid-malignancies-at-ash-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20251208548164r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20251208548164r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neogenomics-to-present-real-world-study-on-comprehensive-genomic-profiling-in-myeloid-malignancies-at-ash-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NeoGenomics to Present Real-World Study on Comprehensive Genomic Profiling in Myeloid Malignancies at ASH 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NeoGenomics to Present Real-World Study on Comprehensive Genomic Profiling in Myeloid Malignancies at ASH 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/neogenomics-to-present-real-world-study-on-comprehensive-genomic-profiling-in-myeloid-malignancies-at-ash-2025\/","og_locale":"en_US","og_type":"article","og_title":"NeoGenomics to Present Real-World Study on Comprehensive Genomic Profiling in Myeloid Malignancies at ASH 2025 - Market Newsdesk","og_description":"NeoGenomics to Present Real-World Study on Comprehensive Genomic Profiling in Myeloid Malignancies at ASH 2025 FORT MYERS, Fla.–(BUSINESS WIRE)– NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, will present new data demonstrating how comprehensive genomic profiling (CGP) can refine diagnosis and guide treatment decisions for patients with myeloid malignancies at the 67th American Society of Hematology (ASH) Annual Meeting, which is being held Dec. 6\u20139, 2025, in Orlando, Florida. The poster, \u201cComprehensive genomic profiling refines diagnosis and reveals actionable fusions in myeloid malignancies: A real-world analysis,\u201d evaluated outcomes using the Neo Comprehensive Myeloid panel, a next-generation sequencing (NGS) assay that provides a complete view of genomic changes in myeloid cancers. By assessing mutations … Continue reading \"NeoGenomics to Present Real-World Study on Comprehensive Genomic Profiling in Myeloid Malignancies at ASH 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/neogenomics-to-present-real-world-study-on-comprehensive-genomic-profiling-in-myeloid-malignancies-at-ash-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-12-08T14:09:43+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20251208548164r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neogenomics-to-present-real-world-study-on-comprehensive-genomic-profiling-in-myeloid-malignancies-at-ash-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neogenomics-to-present-real-world-study-on-comprehensive-genomic-profiling-in-myeloid-malignancies-at-ash-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"NeoGenomics to Present Real-World Study on Comprehensive Genomic Profiling in Myeloid Malignancies at ASH 2025","datePublished":"2025-12-08T14:09:43+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neogenomics-to-present-real-world-study-on-comprehensive-genomic-profiling-in-myeloid-malignancies-at-ash-2025\/"},"wordCount":808,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neogenomics-to-present-real-world-study-on-comprehensive-genomic-profiling-in-myeloid-malignancies-at-ash-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20251208548164r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neogenomics-to-present-real-world-study-on-comprehensive-genomic-profiling-in-myeloid-malignancies-at-ash-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/neogenomics-to-present-real-world-study-on-comprehensive-genomic-profiling-in-myeloid-malignancies-at-ash-2025\/","name":"NeoGenomics to Present Real-World Study on Comprehensive Genomic Profiling in Myeloid Malignancies at ASH 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neogenomics-to-present-real-world-study-on-comprehensive-genomic-profiling-in-myeloid-malignancies-at-ash-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neogenomics-to-present-real-world-study-on-comprehensive-genomic-profiling-in-myeloid-malignancies-at-ash-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20251208548164r1&sid=flmnd&distro=nx&lang=en","datePublished":"2025-12-08T14:09:43+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neogenomics-to-present-real-world-study-on-comprehensive-genomic-profiling-in-myeloid-malignancies-at-ash-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/neogenomics-to-present-real-world-study-on-comprehensive-genomic-profiling-in-myeloid-malignancies-at-ash-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neogenomics-to-present-real-world-study-on-comprehensive-genomic-profiling-in-myeloid-malignancies-at-ash-2025\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20251208548164r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20251208548164r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neogenomics-to-present-real-world-study-on-comprehensive-genomic-profiling-in-myeloid-malignancies-at-ash-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"NeoGenomics to Present Real-World Study on Comprehensive Genomic Profiling in Myeloid Malignancies at ASH 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/917280","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=917280"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/917280\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=917280"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=917280"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=917280"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}